According to Wedbush, Centene CNC estimates are increased.
Wedbush said that it is raising its 2012 estimate $0.21, to $2.68, and increasing its price target to $39 from $38. “Our increased estimates reflect the recent Medicaid Expansion win in Kentucky which we believe could add $0.17-$0.25 on an annualized basis.”
Centene closed yesterday at $36.14.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in